Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NI 2201

Next Previous
Drug Profile

NI 2201

Alternative Names: Anti-CD19 ADC; IKS 03; LCB 73; NI-2201

Latest Information Update: 05 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LegoChem Biosciences; NovImmune SA
  • Developer Iksuda Therapeutics; LigaChem Biosciences; Light Chain Bioscience
  • Class Antibodies; Antineoplastics; Benzodiazepines; Drug conjugates; Immunoconjugates; Immunotherapies; Immunotoxins; Monoclonal antibodies; Pyrroles
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I B-cell lymphoma
  • Preclinical Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 21 Mar 2025 NI 2201 is available for licensing as of 21 Mar 2025
  • 09 Dec 2023 Pharmacodynamics data from a preclinical study in B-cell lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 05 Sep 2023 Phase-I clinical trials in B-cell lymphoma (Second-line therapy or greater, Late-stage disease) in Italy, Spain (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top